Genmab — December 2018
-
-
Jeg tror også omkostningerne med de 3-4 kombinationer er et stort problem. At tro at MM markedet udvikler sig så voldsomt omkostningsmæssigt over de næste år er jo med en forudsætning om, at samfundene og forsikringsselska
berne kan følge med. Men kan de det ? -
Fonsecas top 5 at ASH https://twitter.com/rfonsi1/status/1068586803773374465?s=21
-
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
https://www.prnewswire.com/news-releases/regeneron-presents-positive-data-at-ash-for-regn1979-cd20xcd3-bispecific-antibody-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-300758615.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind